Structure Therapeutics GSBR-1290 Phase 1b shows 4.9% weight loss but Phase 2a obesity data delayed to H1 2024

Structure Therapeutics Inc.

Phase 1b MAD: placebo-adjusted weight loss up to 4.9% at day 28; no severe AEs or discontinuations.
Phase 2a obesity cohort data collection omission: 24 of 40 patients missing week 12 weight; new enrollment; topline now H1 2024.
Phase 2a type 2 diabetes cohort topline still on track for latter half Q4 2023.
Phase 2b studies (T2D ~500 pts, obesity ~275 pts) planned for 2024; formulation bridging study to tablets underway.
GSBR-1290 generally well-tolerated; most AEs mild GI events; no clinically meaningful liver function changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.